VANDA PHARMACEUTICALS INC. Purchase Obligation, to be Paid, Year Two
VANDA PHARMACEUTICALS INC. (VNDA) had Purchase Obligation, to be Paid, Year Two of $7.40 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Commitment and Contingencies › Purchase Obligation, Fiscal Year Maturity › Purchase Obligation, to be Paid, Year Two and Three
us-gaap:PurchaseObligationDueInSecondYear · last filed 2026-08-06
- 2026-06-30: Purchase Obligation, to be Paid, Year Two $7.40M.
- 2026-03-31: Purchase Obligation, to be Paid, Year Two $7.20M.
- 2025-12-31: Purchase Obligation, to be Paid, Year Two $11.00M.
- 2025-09-30: Purchase Obligation, to be Paid, Year Two $9.70M.
| Period end | Purchase Obligation, to be Paid, Year Two |
|---|---|
| 2026-06-30 | $7.40M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.20M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $11.00M 10-K · filed 2026-02-12 |
| 2025-09-30 | $9.70M 10-Q · filed 2025-10-30 |
| 2020-09-30 | $1.00M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $1.00M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.00M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $1.00M 10-K · filed 2020-02-26 |
| 2019-09-30 | $11.20M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $8.75M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $847.00K 10-Q · filed 2019-05-03 |
| 2018-12-31 | $847.00K 10-K · filed 2019-02-19 |
| 2018-09-30 | $5.98M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $6.37M 10-Q · filed 2018-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |